Showing results (401-410 of 793) with videos related to

Sort By:
Pageof 80
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 11, 2013
A phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseRazelle Kurzrock, Peter M Voorhees, Corey Casper, et al.
Molecular Cell|December 27, 2011
Tyrosine phosphorylation of mitochondrial pyruvate dehydrogenase kinase 1 is important for cancer metabolismTaro Hitosugi, Jun Fan, Tae-Wook Chung, et al.
The Lancet. Oncology|June 5, 2019
International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disordersJens Hillengass, Saad Usmani, S Vincent Rajkumar, et al.
Leukemia Research|August 2, 2006
Cytokine and chemokine profiles in multiple myeloma; significance of stromal interaction and correlation of IL-8 production with disease progressionMichael Kline, Kathleen Donovan, Linda Wellik, et al.
Blood|June 26, 2004
VEGF induces Mcl-1 up-regulation and protects multiple myeloma cells against apoptosisSteven Le Gouill, Klaus Podar, Martine Amiot, et al.
American Journal of Hematology|December 23, 2011
Sorafenib, a multikinase inhibitor, is effective in vitro against non-Hodgkin lymphoma and synergizes with the mTOR inhibitor rapamycinVijay Ramakrishnan, Michael Timm, Jessica L Haug, et al.
British Journal of Haematology|December 5, 2009
Impact of dexamethasone responsiveness on long term outcome in patients with newly diagnosed multiple myelomaShirshendu Sinha, S Vincent Rajkumar, Martha Q Lacy, et al.
Blood Cancer Journal|April 23, 2022
Financial toxicity in hematological malignancies: a systematic reviewEvguenia Ouchveridze, Rahul Banerjee, Aakash Desai, et al.
American Journal of Hematology|May 15, 2024
Three-dimensional telomere profiling predicts risk of progression in smoldering multiple myelomaShaji Kumar, S Vincent Rajkumar, Dragan Jevremovic, et al.
Molecular and Cellular Biology|February 19, 2009
Fibroblast growth factor receptor 3 associates with and tyrosine phosphorylates p90 RSK2, leading to RSK2 activation that mediates hematopoietic transformationSumin Kang, Shannon Elf, Shaozhong Dong, et al.
Pageof 80